These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1581 related items for PubMed ID: 35764364

  • 1. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM, Chariou PL, Horn LA, Hicks KC, Palena C, Schlom J, Gameiro SR.
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [Abstract] [Full Text] [Related]

  • 2. Microwave ablation combined with PD-L1 blockade synergistically promotes Cxcl9-mediated antitumor immunity.
    He N, Huang H, Wu S, Ji W, Tai Y, Gao R, Liu Y, Liu Y, Chen L, Zhu D, Zheng X, Jiang J.
    Cancer Sci; 2024 Jul; 115(7):2196-2208. PubMed ID: 38655660
    [Abstract] [Full Text] [Related]

  • 3. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
    Knudson KM, Hicks KC, Ozawa Y, Schlom J, Gameiro SR.
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
    [Abstract] [Full Text] [Related]

  • 4. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM, Khan PP, Wang H, Tsai WB, Qiao Y, Yu B, Larrick JW, Hu MC.
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Janus Silica Nanoparticle-Based Tumor Microenvironment Modulator for Restoring Tumor Sensitivity to Programmed Cell Death Ligand 1 Immune Checkpoint Blockade Therapy.
    Lin X, Li F, Guan J, Wang X, Yao C, Zeng Y, Liu X.
    ACS Nano; 2023 Aug 08; 17(15):14494-14507. PubMed ID: 37485850
    [Abstract] [Full Text] [Related]

  • 7. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
    Reyes RM, Deng Y, Zhang D, Ji N, Mukherjee N, Wheeler K, Gupta HB, Padron AS, Kancharla A, Zhang C, Garcia M, Kornepati AVR, Boyman O, Conejo-Garcia JR, Svatek RS, Curiel TJ.
    J Immunother Cancer; 2021 Apr 08; 9(4):. PubMed ID: 33849925
    [Abstract] [Full Text] [Related]

  • 8. IFN-γ treatment protocol for MHC-Ilo/PD-L1+ pancreatic tumor cells selectively restores their TAP-mediated presentation competence and CD8 T-cell priming potential.
    Stifter K, Krieger J, Ruths L, Gout J, Mulaw M, Lechel A, Kleger A, Seufferlein T, Wagner M, Schirmbeck R.
    J Immunother Cancer; 2020 Aug 08; 8(2):. PubMed ID: 32868392
    [Abstract] [Full Text] [Related]

  • 9. PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages.
    Yamaguchi Y, Gibson J, Ou K, Lopez LS, Ng RH, Leggett N, Jonsson VD, Zarif JC, Lee PP, Wang X, Martinez C, Dorff TB, Forman SJ, Priceman SJ.
    J Immunother Cancer; 2022 Jun 08; 10(6):. PubMed ID: 35738799
    [Abstract] [Full Text] [Related]

  • 10. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
    Bretz AC, Parnitzke U, Kronthaler K, Dreker T, Bartz R, Hermann F, Ammendola A, Wulff T, Hamm S.
    J Immunother Cancer; 2019 Nov 08; 7(1):294. PubMed ID: 31703604
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer.
    Zuo X, Cheng Q, Wang Z, Liu J, Lu W, Wu G, Zhu S, Liu X, Lv T, Song Y.
    Int Immunopharmacol; 2024 Aug 20; 137():112478. PubMed ID: 38901243
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
    Smalley Rumfield C, Pellom ST, Morillon Ii YM, Schlom J, Jochems C.
    J Immunother Cancer; 2020 Jun 20; 8(1):. PubMed ID: 32554612
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors.
    Knopf P, Stowbur D, Hoffmann SHL, Hermann N, Maurer A, Bucher V, Poxleitner M, Tako B, Sonanini D, Krishnamachary B, Sinharay S, Fehrenbacher B, Gonzalez-Menendez I, Reckmann F, Bomze D, Flatz L, Kramer D, Schaller M, Forchhammer S, Bhujwalla ZM, Quintanilla-Martinez L, Schulze-Osthoff K, Pagel MD, Fransen MF, Röcken M, Martins AF, Pichler BJ, Ghoreschi K, Kneilling M.
    Mol Cancer; 2023 Dec 15; 22(1):207. PubMed ID: 38102680
    [Abstract] [Full Text] [Related]

  • 20. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a 177Lu-labeled αPD-L1 antibody.
    Ren J, Xu M, Chen J, Ding J, Wang P, Huo L, Li F, Liu Z.
    Theranostics; 2021 Dec 15; 11(1):304-315. PubMed ID: 33391476
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 80.